National Comprehensive Cancer Network

All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any conflict(s) of interest related to the content of their presentation(s) as defined by the ACCME’s and ANCC’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2 and 6) by experts on the topics.

The speakers listed below have disclosed that they have financial interests, arrangements, or affiliations with the manufacturer of any products or devices to be discussed in this activity or who may financially support the activity:

William Bensinger, MD
Consultant: Millennium Pharmaceuticals, Inc.
Grant/Research Support: Celgene Corporation; Millennium Pharmaceuticals, Inc.; Facet Biotech; Novartis Pharmaceuticals Corporation; Geron; Genzyme Corporation
Product/Speakers’ Bureau: Celgene Corporation; Millennium Pharmaceuticals, Inc.

Irene M. Ghobrial, MD
Product/Speakers’ Bureau: Celgene Corporation; Millennium Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation

Mitchell Smith, MD, PhD
Grant/Research Support: AstraZeneca Pharmaceuticals LP; Eli Lilly and Company; Millennium Pharmaceuticals, Inc.; Pfizer Inc.; Wyeth Pharmaceuticals; Xencor
Product/Speakers’ Bureau: Celgene Corporation; Cephalon, Inc.; Orth Biotech Products, L.P.

Drs. Bensinger, Ghobrial, and Smith have indicated that their presentations will include discussion of investigational or unlabeled uses of commercial products.

The conference planner listed below has disclosed that he has financial interests, arrangements, or affiliations with the manufacturer of any products or devices to be discussed in this activity or who may financially support the activity:

William T. McGivney, PhD*
Advisory Board: Bristol-Myers Squibb Company
Consultant: Mattson Jack DiVinci
Speaker: Center for Business Intelligence; The Confera Group; Health Industry Group Purchasing Association; Japan Comprehensive Cancer Network, Breast; Johnson & Johnson Services, Inc.; Whistler Associates

*All proceeds donated to charitable causes.

The Conference Planning Staff had no financial interests to disclose.

NCCN: Alana L. K. Brody, MBA; Lynn Cherrin, MS; Patricia A. Daulerio; Mark Geisler; Patricia J. Goldsmith; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Lisa G. Kimbro, CPA, MBA; Jennifer L. McCann; Joan S. McClure, MS; Deirdre McKee, MPH; Diane McPherson; Liz Rieder; Shannon K. Ryan; Kelly C. Simpson; and Elizabeth L. Sweeney

Program Goal

The goal of this program is to provide participants with increased knowledge regarding the management of multiple myeloma and discuss the innovative therapies and treatment methods.

Educational Objectives

Following this activity, participants should be able to:

Identify novel therapies and optimal induction therapies for patients with newly diagnosed multiple myeloma
Assess the evidence for the use of novel agents, such as bortezomib and lenalidomide, in the first-line setting
Utilize current data to improve patient selection for therapy and individualize treatment plans

Intended Audience

This educational activity is designed to meet the needs of physicians, nurses, and other clinical professionals who manage patients with cancer.

Activity Instructions

Continuing education credit will be awarded to participants who listen to the presentation and complete the evaluation. Participants should review the learning objectives and faculty disclosure statements prior to listening to a presentation in its entirety. You must be connected to the Internet in order to review and complete the evaluation form. A statement of credit will be electronically generated once you complete the evaluation form. To receive credit, this activity must be completed no later than May 20, 2010. There is no fee for participating in this activity.

Download Podcast

Listen to MP3

Podcast Evaluation

Accreditation Information

Physicians

The National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

NCCN designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nurses

This activity is approved for 1.5 contact hours. National Comprehensive Cancer Network is an approved provider of continuing nursing education by the PA State Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.

Approval as a provider refers to recognition of educational activities only and does not imply ANCC Commission on Accreditation or PA Nurses approval or endorsement of any product.

Kristina M. Gregory, RN, MSN, OCN, is our nurse planner for this educational activity.

Release date: May 20, 2009
Expiration date: May 20, 2010

Commercial Support

Supported by educational grants from Celgene Corporation and Millennium Pharmaceuticals, Inc.

E-mail

Mark A A Size